Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

827
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
827
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

926
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
926

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Validation of the Roche cobas and cobas 4800 Human Papillomavirus Tests on Self-Collected Vaginal Dry Swabs versus Practitioner-Collected Cervical Specimens Using the VALHUDES Protocol.

The Journal of molecular diagnostics : JMD·2026
Same author

In-Culture Antibody Capture Using Transient CHO Expression Systems.

Bio-protocol·2026
Same author

The journey after restart: understanding the multidimensional experience of cardiac arrest survivors.

Singapore medical journal·2026
Same author

What Factors Increase the Risk of Dislocation After Primary Total Hip Arthroplasty Using the Direct Anterior Approach?

The Journal of arthroplasty·2026
Same author

What are medical students really doing with GenAI in their self-study? An epistemic entanglement framework approach.

Medical teacher·2026
Same author

Lymph node dissection during cystectomy for non-muscle-invasive bladder cancer: A systematic review.

BJUI compass·2026

Related Experiment Video

Updated: May 1, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

4.0K

Neoadjuvant ADT for Asian Patients Undergoing Robotic Radical Prostatectomy Is the Conversation Over?-A

John Joson Ng1, Sean Lim2, Alvin Lee2

  • 1Duke-NUS Medical School, Singapore 169857, Singapore.

Cancers
|February 27, 2026
PubMed
Summary

Neoadjuvant androgen deprivation therapy (ADT) before radical prostatectomy (RP) significantly reduces cancer spread and recurrence. This study found ADT improved outcomes in specific high-risk prostate cancer patients without increasing surgical complications.

Keywords:
ADTneoadjuvantprostate cancerradical prostatectomysurgery

More Related Videos

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.8K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.6K

Related Experiment Videos

Last Updated: May 1, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

4.0K
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.8K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.6K

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Neoadjuvant androgen deprivation therapy (ADT) before radical prostatectomy (RP) lacks conclusive evidence and is not routinely recommended.
  • Evaluating ADT's impact on surgical and oncologic outcomes is crucial for treatment optimization.

Purpose of the Study:

  • To assess the effect of neoadjuvant ADT on surgical and oncologic outcomes in patients undergoing RP.
  • To identify patient subgroups that benefit most from neoadjuvant ADT.

Main Methods:

  • Retrospective analysis of 1091 patients undergoing RP (2013-2024).
  • 105 patients received neoadjuvant ADT, 986 did not.
  • 1:1 propensity score matching created 105 matched pairs to compare outcomes.

Main Results:

  • Neoadjuvant ADT significantly reduced extracapsular extension, positive surgical margins, and lymph node involvement.
  • Biochemical recurrence rates were significantly lower in the neoadjuvant ADT group post-matching (4.8% vs. 18.1%).
  • No significant differences in operative time, blood loss, length of stay, or complication rates were observed.

Conclusions:

  • Neoadjuvant ADT before RP effectively reduces locoregional spread and biochemical recurrence.
  • Benefits were most pronounced in high-risk patients (PSA density ≥ 0.20, Gleason score ≥ 8, clinical T3 disease).
  • Prospective trials are warranted to confirm these findings and guide clinical practice.